Biopharma executive · Translational strategist
I connect scientific and clinical evidence with development strategy, partnerships, valuation and financing—helping complex healthcare technologies move forward with greater clarity.
Vice President of Innovation & Corporate DevelopmentBonus Biogroup
About
Healthcare technologies move—or stall—at the intersection of evidence, clinical development, manufacturing, regulation, market strategy, organizational execution and capital.
My work brings those dimensions into one decision framework. Over more than 15 years, I have moved from research and translational leadership into corporate development, partnerships, valuation, financing and board support—while staying grounded in how the science actually works.
The goal is not to remove complexity. It is to make complexity decision-ready.View awards & recognition
Selected work & impact
A selection of programs where scientific, clinical and organizational choices had to become one coherent strategy.
Translational program leadershipMesenCure
As co-inventor and scientific and program leader, I helped advance an allogeneic primed mesenchymal stromal cell therapy from discovery through clinical planning—connecting mechanism, development logic, operations and external communication.
Strategy & external positioningBonoFill
For an autologous tissue-engineered product, the strategic question extends far beyond clinical performance. My work connects clinical evidence, manufacturing, regulatory and quality considerations, market positioning, financing and partner needs.
NanoGhosts
Led translational work and licensor-side technology transfer for a cell-derived nanovesicle platform entering an aMoon-backed venture, spanning IP, diligence, fundraising and stakeholder alignment.
Technology transfer · Venture formationSingapore · Nanyang Technological University
At Nanyang Technological University, I established regenerative-medicine research infrastructure, coordinated the procurement and commissioning of multi-million-dollar scientific equipment, and led an international team working in cardiac restoration and tissue engineering. I also developed and led the graduate course Statistical Analysis of Experimental Data, continuing as invited lecturer-in-charge through 2016.
International leadership · Scientific infrastructure · Graduate teachingCapabilities
The strongest decisions connect scientific truth, development reality and the capital required to execute.
Evaluate scientific opportunities through the combined lens of evidence, strategic fit, development feasibility and value creation.
Turn complex program choices into a coherent path across indication, evidence, milestones, risk and capital allocation.
Connect discovery, preclinical, clinical and operational teams around the decisions that move a program forward.
Shape licensor-side diligence, IP positioning, stakeholder alignment and the practical work of moving technology between organizations.
Translate scientific and development assumptions into investor-ready narratives, valuation logic and financing priorities.
Make complex scientific and strategic ideas legible to boards, partners, investors and wider audiences—through decision materials, talks, articles and visual explainers.
Research, writing & media
Let's connect
I welcome thoughtful conversations with biotech and pharma leaders, investors, academic institutions, technology-transfer organizations and strategic partners.
tomer@tomerbronshtein.com